An employee conducts research at a biomedical information center in Beijing. [Photo by Zhang Bei/For China Daily] BEIJING -- China's homegrown drug Sintilimab designed for treating relapsed or refractory classic Hodgkin lymphoma has won international recognition, with its clinical trial research published as the cover paper in the January issue of The Lancet Haematology. Hodgkin lymphoma is a rare malignant lymphoma that occurs mostly in young people between the ages of 20 and 40. Although the cure rate of early treatment is high, patients have a 20 percent chance of recurrence after their first treatment. Patients with relapsed or refractory classic Hodgkin lymphoma lack effective treatment in China. Sintilimab, an anti-PD-1 drug, is a kind of checkpoint inhibitor, an emerging anti-cancer therapeutic modality that boosts the immune system to help the body target and kill tumors. Professor Shi Yuankai from the Cancer Hospital, Chinese Academy of Medical Sciences, led the clinical research, which enrolled 96 patients with relapsed or refractory classic Hodgkin's lymphoma from 18 hospitals in China. Results showed that Sintilimab has favorable activity and acceptable toxicity in Chinese patients with relapsed or refractory classical Hodgkin lymphoma, with 80.4 percent of the patients showing an objective response. Stephen M Ansell from the Division of Hematology at the Mayo Clinic commented that Sintilimab is a highly effective treatment which potentially improves the outcomes of patients with classical Hodgkin lymphoma worldwide. Sintilimab was approved for market authorization by China's National Medical Products Administration in December 2018. The approval will bring more treatment options for cancer patients in China, Shi said. rubber bracelets canadaevent wristbands
FUZHOU - A containment dome has been installed on a reactor at China's nuclear power project using Hualong One technology, a domestically-developed third generation reactor design.The dome, weighing 342 tonnes and measuring 46.8 meters in diameter, was installed using a crane on the No. 6 nuclear power unit in Fuqing, Southeast China's Fujian province at Wednesday, according to the China National Nuclear Corporation (CNNC).The installation was finished ten days ahead of schedule, marking the completion of civil works and the beginning of the assembly stage, the CNNC said.The dome ensures the nuclear reactor is well sealed, preventing radioactivity and other nuclear accidents."Considering its weight and volume, the installation was very demanding," said Liu Bin, an official with the nuclear project.The dome was the second of its kind using Hualong One design installed on a reactor. The first, on the No. 5 unit, was completed last May.Hualong One reactors were jointly designed by two nuclear power giants, China General Nuclear Power Group and CNNC, and passed inspection by a national panel in August 2014.China has since approved the use of Hualong One technology to build two reactors in Fujian, the No. 5 and No. 6 units.Hualong One reactors are among six units at the Fuqing nuclear project, of which four units have already been put into commercial operation.It is estimated that the four operating units have generated more than 55 billion kwhs of electricity, cutting about 22 million tonnes of standard coal consumption and over 71.8 million tonnes of carbon dioxide.
